Best Biologics / mAb CDMOs in Asia

← All Biologics CDMOs Best Clean FDA History Commercial Scale

Region: USA Europe Asia

CDMOs tracked

Fully scored

With FDA records

FDA inspections

EMA/MHRA GMP certs

Warning letters

For Asia-manufactured biologics / mab programs, Ajinomoto Bio-Pharma Services, Lotte Biologics, and Piramal Pharma Solutions lead CDMO Signal's ranking of biologics / mab CDMOs with confirmed Asian manufacturing sites. Filtered from the global directory of 31 scored biologics / mab CDMOs to 9 with Asia-Pacific facility presence. Asian CDMOs cover a range of regulatory jurisdictions — PMDA (Japan), NMPA (China), MFDS (South Korea), CDSCO (India) — each with distinct requirements. For sponsors supplying US and EU markets, cross-jurisdictional regulatory posture (FDA and EMA/MHRA inspection history on Asian facilities) is typically the qualifying signal. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.

Biologics CDMOs manufacture monoclonal antibodies, fusion proteins, and other large molecules in mammalian (typically CHO) cell culture. It is the largest and most mature segment of contract manufacturing, spanning early clinical supply through multi-thousand-litre commercial production.

Selecting a biologics CDMO turns on bioreactor scale and modality fit (mAb, bispecific, fusion protein), titer and cell-line strategy, fill-finish, and — above all — a clean regulatory record at commercial scale. The rankings below score each CDMO on FDA inspection history, EMA/MHRA GMP certification, clinical-program activity, and capacity.

FDA inspection outcomes across these CDMOs: 5 NAI (no action), 7 VAI (voluntary action), 1 OAI (official action). Leading inspection & GMP sites: UNITED KINGDOM (8), India (7), United States (5), INDIA (4), Denmark (3).

Last updated 2026-07-29. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	AJ Ajinomoto Bio-Pharma Services San Diego, CA · Osaka, JP	85.6	100.0	0 insp · 1 GMP	—	0 programs
2	LB Lotte Biologics Incheon, KR · Syracuse, NY	83.7	100.0	1 insp · 0 GMP	—	0 programs
3	PR Piramal Pharma Solutions Lexington, KY · Riverview, MI · Ahmedabad, IN	83.6	95.7	5 insp · 13 GMP	—	0 programs
4	SG Syngene International Bengaluru, India	79.7	95.9	2 insp · 0 GMP	—	0 programs
5	PBI ProBio Taipei, Taiwan	78.1	100.0	0 insp · 9 GMP	—	0 programs
6	SI Simtra BioPharma Solutions Bloomington, IN · Halle, DE	78.1	100.0	0 insp · 1 GMP	—	0 programs
7	AU Aurigene Pharmaceutical Services Hyderabad, India	63.0	—	—	—	0 programs
8	SS Singota Solutions Bloomington, IN	59.0	—	—	—	0 programs
9	IC INCOG BioPharma Services Fishers, IN	56.5	—	—	—	0 programs
—	BioCina Adelaide, Australia	Profiled	—	—	—	0 programs
—	Altruist Biologics Suzhou, China	Profiled	—	—	Available	0 programs
—	Sun Pharmaceutical Industries Ltd. Mumbai, India	Profiled	—	5 insp · 0 GMP	—	0 programs
—	Bora Pharmaceuticals Taipei, Taiwan	Profiled	—	—	—	0 programs
—	TaiMed Biologics Zhubei City, Taiwan	Profiled	—	—	—	0 programs
—	Biological E. Limited (BioE) Hyderabad, India	Profiled	—	—	—	0 programs
—	Aurobindo Pharma (Sterile Injectables Division) Hyderabad, India	Profiled	—	—	—	0 programs
—	BE Biosol (formerly SGI Pharma / Biological E, Samirpet) Hyderabad, India	Profiled	—	—	—	0 programs
—	Eli Lilly (Internal Manufacturing — Lebanon, IN) Indianapolis, IN	Profiled	—	—	—	0 programs
—	Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) Lianyungang, China	Profiled	—	—	—	0 programs
—	Laurus Labs Hyderabad, India	Profiled	—	—	—	0 programs
—	Daiichi Sankyo (Manufacturing / Daiichi Sankyo Propharma) Tokyo, Japan	Profiled	—	—	—	0 programs

How we score CDMOs →

What to evaluate in a Biologics / mAb CDMO

Scale & bioreactor fit

Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct.

Cell line & process development

Ask whether the CDMO offers its own expression platform/cell line or works from yours, and how process development and tech transfer are handled.

Regulatory track record

Biologics programs heading to BLA/MAA need a strong commercial-scale inspection history. Cross-check FDA 483s, warning letters, and EMA/MHRA GMP coverage — all shown above.

Drug substance to drug product

Confirm whether the CDMO covers fill-finish and formulation in-house or coordinates a separate site, which affects timelines and comparability.

Regulatory landscape across PMDA (Japan), NMPA (China), MFDS (South Korea)

Asian biopharma manufacturing spans multiple national regulators. PMDA (Japan) is generally regarded as one of the most stringent in Asia, with GMP requirements broadly aligned with FDA and EMA. NMPA (China) has substantially strengthened its GMP framework over the past decade, and Chinese CDMOs increasingly hold FDA and EMA certifications alongside NMPA registration. MFDS (South Korea) certification is standard for Korean CDMOs. For sponsors supplying US or EU markets, the qualifying signal for an Asian CDMO is typically FDA and EMA inspection history on the specific facility — which the Signal Score's Quality Compliance pillar captures directly.

Which Asian CDMOs cover FDA (US) and EMA/MHRA (Europe) regulatory geographies?

Asian CDMOs with US FDA and European EMA/MHRA inspection history are qualified to supply global markets; those without cross-jurisdictional inspection posture are typically limited to their home-market regulatory scope. The Signal Score's Quality Compliance pillar includes FDA + EMA + MHRA data directly, so Asian CDMOs with cross-jurisdictional certification typically rank higher on this pillar than home-market-only competitors. Sponsors evaluating an Asian CDMO for a US or EU program should cross-check with the US region ranking and Europe region ranking — CDMOs appearing across regions have demonstrated multi-jurisdictional posture.

Recent US regulatory events affecting Asian CDMO selection (WuXi 1260H, BioSecure Act considerations)

Asian CDMOs — particularly Chinese-headquartered players — are subject to US regulatory events that affect sponsor risk assessment. The US Department of Defense's 1260H list (which added WuXi AppTec in June 2026) and the BioSecure Act (proposed federal legislation restricting federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies) are both active considerations. CDMO Signal's platform does not encode US political risk into the Signal Score directly — the composite reflects regulatory quality, operations, financial stability, and capacity signals. Sponsors weighing an Asian CDMO for a US-supplying program should evaluate US regulatory risk separately as a distinct decision layer alongside the Signal Score-based capability assessment.

Biologics / mAb CDMOs — Frequently Asked Questions

Who are the top Biologics / mAb CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked Biologics / mAb CDMOs include Ajinomoto Bio-Pharma Services, Lotte Biologics, Piramal Pharma Solutions. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many Biologics / mAb CDMOs have FDA inspection records?

CDMO Signal tracks 4 Biologics / mAb CDMOs with FDA inspection records and 24 EMA/MHRA GMP certificates across the group.

What should I look for in a biologics CDMO?

Match bioreactor scale and modality (mAb, bispecific, fusion protein) to your program, confirm cell-line and process-development support, and prioritize a clean FDA and EMA/MHRA record at the scale you'll commercialize at.

What is the difference between a biologics CDMO and a cell or gene therapy CDMO?

Biologics CDMOs make large molecules (antibodies, proteins) in bioreactors at litre-to-thousands-of-litre scale. Cell and gene therapy CDMOs make living cells or viral vectors in much smaller, often per-patient batches under different containment and analytics.

Related modalities

Recombinant Proteins CDMOs mRNA / LNP CDMOs Cell Therapy CDMOs

Other Modalities

AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC